### Breast Cancer Clinical Trials

**ALLIANCE- Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (Feig)**

**UCI 15-83 Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (Tromberg)**

**UCI 10-39 Predicting, Pathologic Response w/in the 1st Week of Neoadjuvant ChemoTx Using Functional Parameters Measured Using Diffuse Optical Spectroscopic Imaging (Tromberg)**

**UCI 11-15 Correlation of Clinical & MRI Finding w/ Prognosis of Breast CA Patients (Su)**

**UCI 11-21 Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (Su)**

**UCI 14-86 Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (Su)**

**UCI 14-85 Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (Su)**

**UCI 16-23 A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer –(WISDOM Study)-Women Informed to Screen Depending On Measures of Risk (Anton-Culver)**

---

**Measurement of Breast Optical properties (Tromberg)**

**ATHENA Breast Health Network (Anton-Culver)**

**Development of a Quantitative Tissue Optical Index of Breas Density for Prediction of Hormone Therapy Response (O’Sullivan)**

**Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by mastectomy in Stage I, II, Ill Breast Cancer (Daroui)**

**Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)**

**Breast Tumor Oxygenation During Exercise (Tromberg)**

**A Self-discovery tool for Latina Breast cancer Survivors (Sorkin)**

**A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery (Police)**

**(PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)**

---

**For more details contact 1-877-UC-STUDY or ucstudy@uci.edu**

**opening soon** 1017
Breast Cancer Therapeutic Clinical Trials

**Breast Cancer**

- **Adjuvant**
- **Neo-Adjuvant**

**Multiple Disease Site**

- UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

**Stage I-III**

- UCI 14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

**HER2- High Risk**

- SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. (Nangia)

- SWOG S1418 Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (Nangia)

**Hormone+ High Risk**

- Alliance A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Nangia)

- NSABP B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Darou)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**opening soon**
Breast Cancer Therapeutic Clinical Trials

**Advanced**

**UCI 17-45**
COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease (Parajuli)

**Metastatic**

**Targeted therapy**

**ECOG-EAY131** (MATCH)-Molecular Analysis for Therapy Choice (Seery)

**NRG BR002** A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (Darouie)

**UCI 16-74** A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)

For more details contact 1-877-UC-STUDY or ucsstudy@uci.edu **opening soon**